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1. Introduction 
Implantable cardioverter defibrillators (ICDs) use has increased exponentially during the past 
decade. However, these devices are associated with complications related to the implantation 
procedure itself and morbidity caused by the adverse functioning of the components 
comprising the system. In 2003, 10.8% of patients undergoing cardioverter-defibrillator 
implantation experienced one or more early complications (Reynolds et al., 2006). Acute 
implantation complication rates range from 3% to 7%. For this reason a controlling in respect 
to the technology, indications for use, personnel involved in monitoring and the frequency and 
types of monitoring events is needed (Wilkoff et al., 2008).  
The European Community (EN540, European Standard, 1993) and the International 
Standards Organization (ISO 14155, International Standard, 1996) have provided standards 
for adverse events observed during trials with implantable medical devices, defining an 
adverse event as any undesirable clinical occurrence in a subject whether it is considered to 
be device related or not. These standard criteria underwent sweeping changes in the past 
time. The first and most evident change is the standard’s new title: “ISO 1415: Clinical 
investigations of medical devices in human subjects – good clinical practices”, harmonized 
with the ICH E6 GCP guidelines (Stark et al., 2011). Few studies have systematically 
examined the predictors of complications in this population using multivariable analysis. 
These data suggest that complications are driven by the 3 major components that contribute 
to risk: device, physician, and patient factors. This may be most relevant for patients with 
complex device systems, particularly heart failure patients (Curtis et al., 2009; Al-Khatib et 
al., 2008). Even though prospective studies defining the risk associated with ICD 
implantation and optimal peri-, intra- and postoperative management to ICDs are needed. 
Therefore the aim of this review was to report the incidence of adverse events during the 
initial months after pectoral implantation or replacement of an ICD system with a 
transvenous lead system. The usual complication including implant procedure-related 
complications, ICD generator-related complications, as well as lead-related complications 
will be discussed. This review, however, limits discussion to surgical complications. In 
addition, it will be reviewed the relevant clinical trials as well as prescription guidelines, 
because the increasing clinical relevance of this topic is the reason for the future formulation 
of recommendations by an interdisciplinary working group. 
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2. Implant procedure-related complications 
The early mortality effects of implant procedure-related complications may be the direct 
“mechanical” effect of the procedure, such as infection, pneumothorax, or perforation, that 
are not well tolerated. These risks probably are largely related to procedural complexity, 
reflected in system configuration risk in procedural volume, and operator expertise. The 
second contributor is the patient; the physiological duress of even minor surgery may 
exacerbate comorbidities, particularly heart failure, which contributes significantly to 
reduced survival.  
2.1 Venous access related complications 
Transvenous non-thoracotomy lead systems are available and are usually implanted safely 
and with a high success rate by an electrophysiologist and a surgeon. The axillary and 
subclavian vein puncture are the standard approach in ICD implantation. However, 
obtaining venous access for defibrillator implantation can be complicated by vascular injury, 
subclavian arteriovenous fistula and/or pneumothorax or hemothorax. No-puncture 
strategy using the cephalic cut-down technique obviates the complication in the majority of 
cases and improves the safety of device implantation. Thus, the subclavian route of insertion 
resulted in more complications than the cephalic vein route (Kron, 2003). In addition, 
conventional transvenous approaches for ICD lead placement are not possible in some 
patients with limited vascular access and/or tricuspid valve dysfunction. On the other site 
transvenous ICD lead failure rates are significant and their occurrence increases with time 
from implant. Therefore it was recently designed an entirely subcutaneous ICD system to 
eliminate the need for venous access and their complication (Bardy et al., 2010). 
2.1.1 Subclavian arteriovenous fistula 
Subclavian arteriovenous fistula is a rare and uncommon complication of ICD implantation 
and it could be successful closured using an Amplatzer vascular occlusion plug (Hess et al., 
2010). 
2.1.2 Pneumothorax 
Pneumothorax is usually a complication of subclavian venous access and may be detected 
during the procedure or delayed until 48 h after implantation (Aggarwal at al., 1995). This 
complication is a problem in unexperienced operators and is directly related to the difficulty 
of the subclavian puncture. Often is the pneumothorax asymptomatic, but uncommonly 
occurs a tension pneumothorax with hemodynamic and clinical improvement, which needs 
immediately placement of chest tube. The diagnosis of pneumothorax was confirmed by 
chest x-ray. Pneumothorax due to perforation of the atrial lead through the wall of the atrial 
appendage has already been reported (Rosman et al., 2006). Perforation of the right ventricle 
with or without pericardial effusion is also well recognized (Gondi et al., 1981). However, 
isolated pneumopericardium reported as an exclusive complication of a cardiac 
resynchronisation therapy (CRT) implantation is very uncommon. We have previously 
reported pneumothorax recognised days after CRT implantation and concomitant 
pneumopericardium secondary as a late complication of a persisting connection between the 
pericardium and the pleura parietalis as consequence of the former aortal-coronary surgery, 
three years after coronary artery bypass graft surgery (CABG) (Fig.1, Parahuleva et al., 
2009).  
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Fig. 1. Computed tomography (CT) scan of the thorax showing (A) left-sided pneumothorax 
with 30% reduction in lung volume and (B) moderate- sized pneumopericardium and 
pleuromediastinum (from Parahuleva et al., 2009). 
2.1.3 Hemothorax 
Hemothorax results most commonly from an arterial puncture and cannulate the artery 
with the intraducer, a situation that should indicate vascular surgical removal. This 
complication could also occur after right ventricular (RV) lead perforation beyond the 
cardiac border into the pleural space (Merla et al., 2007). The diagnosis of hemothorax and 
suspecting of RV perforation in patients with ICD implantation presenting with recurrent 
chest pain and/or pleural effusion is important, because it is potentially life threatening 
complication. Massive hemothorax may develop after placement of an ICD in patients who 
received postoperative anticoagulants (see also 2.2.1 ICD Hematoma). The perioperative 
management of anticoagulation in patients who are having implantation of a pacemaker or 
ICD is a common clinical problem in which best clinical practise is not established, but a 
strategy involving postoperative bridging with intravenous heparin confers a high risk for 
bleeding whereas perioperative continuation of a oral anticoagulation appears to reduce the 
risk for bleeding (see also 2.2.1 ICD Hematoma). 
2.1.4 Venous thrombosis and superior vena cava syndrome (SVCS) 
Significant vein occlusion was found in 25% of patients after placement of ICD (Lickfett et 
al., 2004) and in 27% of patients after pacemaker implantation (Antonelli et al., 1989). 
Subclavian venous obstruction or thrombosis following transvenous device implantation 
rarely cause clinical problems and become a significant challenge, when lead revision or 
device upgrade is indicated (Wilkoff et al., 2004, van Rooden et al., 2004). The reasons for 
these venous complications such as stenosis, occlusions, and superior vena cava syndrome 
have been discussed. The study has suggested that intravenous lead infection promotes 
local vein stenosis (Korkeila et al., 2009). Another found that the presence of a temporary 
wire before implantation is associated with an increased risk of stenosis (Haghjoo et al., 
2007). Despite many years of experience with transcutaneous implanted intravenous pacing 
systems, it was unable to identify clear risk factors which lead to venous stenosis (Bar-
Cohen et al., 2006). Neither the hardware (lead size, number and material) nor the access site 
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choice (cephalic cut down, subclavian or axillary puncture) appears to affect rate of venous 
complications. A few factors were proposed as predictors of severe venous 
stenosis/occlusion: presence of multiple pacemaker leads (compared to a single lead), use of 
hormone therapy, personal history of venous thrombosis, new onset of atrial fibrillation,  the 
presence of temporary wire before implantation, previous presence of a pacemaker (ICD as 
an upgrade) and the use of dual-coil leads (Bulur et al., 2010). A variety of different 
strategies to overcome the venous obstruction have been reported: controlateral LV lead 
placement (Fox, 2006), innominate vein as an alternative venous access (Aleksic et al., 2007), 
internal jugular vein approach (Bosa-Ojeda et al., 2007), opening an occluded subclavian 
vein and venoplasty (Worley et al., 2007), surgical approaches with the use of minimally 
invasive procedures (Jaroszewski et al., 2009), supraclavicular vein approach (Antonelli et 
al., 2010), use of a tunneling technique (Kim et al., 2010) or iliofemoral approach by patients 
with occluded superior venous access (Allred et al., 2008).  
Anticoagulant therapy (for other reasons than pacemaker lead) seemed to have protective 
antithrombotic effect (Pavia et al., 2001), but the effect of prophylactic anticoagulant 
treatment after pacemaker implantation have not found positive results (Goto et al., 1998). 
Furthermore, it was found that oral anticoagulant treatment did not differ from antiplatelet 
treatment in respect to protection from venous obstruction occurrence (Haghjoo et al., 2007). 
The patients who are candidates for multiple pacemaker leads implantation have more risk 
factors for venous obstruction than other device patients. These patients should be 
evaluated with venography before lead revision and/or device upgrade procedures. In 
addition, large studies are needed to investigate whether anticoagulant or antiplatelet 
treatment could prevent venous obstruction. 
2.2 ICD pocket related complications 
2.2.1 ICD hematoma 
Pocket hematoma is an acute, relatively common complication. The use of electrocautery 
and portable drainage device for 24 hours after implantation are useful to minimize pocket 
hematoma. The hematomas are managed usually conservatively. Expanding in size of 
hematoma, tense or painful in the ICD pocket are requiring re-operation to evacuate the 
hematoma (Belott et al., 2000). The risk of pocket hematoma is increased in anticoagulated 
patients. Dual antiplatelet therapy and periprocedural heparin appears to be associated with 
significantly increase risk of bleeding complications at the time of pacemaker or ICD 
implantation (Al-Khadra et al., 2003; Giudici et al., 2004). The study of Tompkins 
(Tompkins, 2010) evaluated patients (n=1388) undergoing permanent pacemaker and ICD 
implantation over a 3-year period to determine if patients with antiplatelet or 
anticoagulation therapy required normalization of coagulation factors in the periprocedural 
period. A significant bleeding complication was defined as need for pocket exploration or 
blood transfusion, hematoma requiring pressure dressing or change in anticoagulation 
therapy, or prolonged hospitalization.  It has been shown that continuation of warfarin was 
associated with a trend toward increased bleeding complications when compared with 
controls, even when held to allow the international normalized ratio (INR) to decrease 
below 1.5 (Fig.2). There was no statistical difference in bleeding risk between patients 
continued on warfarin with an INR≥1.5 and patients who had warfarin withheld until the 
INR was normal. The use of periprocedural heparin (enoxaparin or unfractionated heparin) 
and dual antiplatelet therapy increase the risk of bleeding complication (Fig.2). 
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Appropriate periprocedural management requires a thorough understanding of indications 
for antiplatelet or anticoagulation medications and assessing the risks of thromboembolic 
versus bleeding complications (Douketis et al., 2008). Brake off of antiplatelet or 
anticoagulation medications before device implantation could be possible in patients at low 
risk for thromboembolic events. Patients at high risk for thromboembolic events should 
continue warfarin throughout the periprocedural phase and should need bridging 
anticoagulation with therapeutic dose heparin.  
Operating with oral anticoagulation is the best alternative, because device implantation or 
replacement without withdrawing of oral anticoagulants and with an INR of about 2.0 is 
safe and was not associated with an increase of the hemorrhagic risk. 
 
 
Fig. 2. Effect of antiplatelet and anticoagulation agents on bleeding complication in patients 
after device implantation (modified from Tompkins et al., 2010). 
2.2.2 ICD infections 
Device system infection is a serious complication and tended to occur within 1 year after 
implantation, or as late onset lead endocarditis (Mangram et al., 1999). The physical 
manifestations range from mild symptoms with local reaction to fulminant sepsis. Failure to 
use perioperative antibiotics is a predictor of system infection and ICD system infection 
ranges from 0.13 to 12.6% (Mela et al. 2001). Repeated operative procedures after the first 
device implantation were associated with increased risk of device infection (Margey et al., 
2010). Female sex, older age, and preoperative antibiotics given at the first device 
implantation were associated with a lower risk of later device infection (Johansen et al., 
2011). End-stage renal disease markedly increases bleeding and device-related infections 
(Tompkins, 2011). 
When infection is present, complete device removal with transvenous lead extraction must 
be followed by antimicrobial therapy. Removal of the entire pacing system is crucial for the 
treatment of lead endocarditis (see also 3.2. Lead extraction-related complication). The 
development of laser-assisted extraction techniques for chronically implanted pacemaker 
and defibrillator leads has reduced the need for open surgical removal (Gaca et al., 2009). 
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2.2.3 ICD wound dehiscence and erosion 
Wound healing is a major determent in the post-surgical course of patients after device 
implantation. Insufficient closure may lead to serious complications with pocket infections 
leading to the device's explantation. Therefore is the skin suture approach most important 
for the wound healing. The absorbable intracutaneous suture is frequently used to close 
surgical incisions and a form of skin adhesive surgical tape is commonly also placed over 
the wound. It was shown that early adverse events as insufficient closure, major and minor 
bleeding, pocket haematoma, erythema, incrustation, dehiscence, keloid, and explantation 
due to infection occurred significantly more often in the patients with skin adhesive in 
comparison to absorbable intracutaneous suture (Spencker et al., 2011). 
Skin erosion is possible when the subcutaneous pocket at the time of initial implantation is 
too small or too superficial and the device makes undue tension on the overlying skin. The 
skin erosion is also associated with potential pocket infection and sub-pectoral placement 
after complete explantation of the device-lead system is usually advised (Gold et al., 1996).  
2.2.4 Chronic pain 
Chronic pain will usually manifest an obvious infection. An allergy to nickel/cobalt and 
chronic painful eczema could mimic a pocket infection (Citerne et al., 2011). Alternatively, 
mechanical trauma from the device location adjacent to chest wall may also be the reason for 
chronic pain. In this situation device relocation revision may be advised. 
2.2.5 Twiddler’s syndrome 
Twiddler’s syndrome is a rare complication well described in patients with subcutaneous 
permanent pacemakers, but is unusual in patients with CRT-D, which typically presents 
with device malfunction and inappropriate shocks. The condition occurs when the patient, 
either consciously or unconsciously, rotates the implanted pacemaker in its pocket, resulting 
in torsion, dislodgement, and often fracture of the pacing lead (Veltri et al., 1984). The 
placement of the pulse generator in a sub-pectoral position may help prevent Twiddler’s 
syndrome. 
2.3 Perioperative ICD implantation related-complications 
2.3.1 Perioperative death 
A serious complication such as perioperative death is rare in patients with transvenous 
device implantation. Elevated BNP level was significantly associated with increased risk of 
cardiac arrest periprocedural in patients received ICD implants (Wei et al., 2011) and studies 
are needed to investigate whether reducing preprocedural BNP could manage the 
procedural risk of cardiac arrest or in-hospital mortality. Although the benefit of ICD 
therapy in patients with hypertrophic cardiomyopathy (HCM) at risk for sudden cardiac 
arrest is well established, there may be a higher risk for device complications and 
inappropriate shocks (Lin et al., 2009). 
2.3.2 Strokes 
The most patients with perioperative strokes after device implantation had chronic atrial 
fibrillation without prior oral anticoagulation. Therefore, it would be routinely performed 
transesophageal echocardiography prior to device implantation in patients lacking 
maintained anticoagulation despite increased risk for cardiac thromboembolism, e.g., atrial 
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fibrillation, severely reduced left ventricular function, ventricular aneurysms, and 
intracardiac thrombi. In the presence of intracardiac thrombi is not recommended to 
perform intraoperative defibrillation threshold testing (Healey et al., 2010). 
2.4 Defibrillation testing-related complications 
Defibrillation threshold (DFT) testing has traditionally been an integral part of ICD 
implantation. However, recent publications question the necessity of DFT testing during 
implantation, because of compelling evidence that it predicts or improves outcomes 
(Strickberger et al., 2004; Russo et al., 2005; Gula et al., 2008). DFT testing may now be the 
highest acute risk component of ICD implantation, quoting the effectiveness of the current 
generation of devices and the rate of complications associated with testing. The recently 
published experience revealed some serious testing-related complications: sudden cardiac 
death (SCD), spontaneous episodes of ventricular arrhythmia (sustained ventricular 
tachycardia, VT, and strokes (Birnie et al., 2008). Physicians favored performance of 
defibrillation testing in patients who are at lower risk of defibrillation testing-related 
complications and in those receiving amiodarone (Ruso et al., 2005). Lower left ventricular 
ejection fraction (LVEF) had a borderline predictive value for high DFT. The association 
between left ventricular function and failure of defibrillation was examined in the Post 
Implant Testing Study (PITS). As systolic function declined, there was a trend to a higher 
failure rate, which was not statistically significant (Brodsky et al., 1999). Other studies 
suggest that left ventricular mass or volumes are more predictive than ejection fraction to 
predict DFTs (Hodgson et al., 2002). The rate of complications associated with intraoperativ 
DFT testing appears small, even allowing for the underestimation of its true rate with the 
current study methodology (Birnie et al., 2008; Healey et al., 2010). These slight but 
measurable risks must be considered when assessing the risk-benefit ratio of the procedure. 
The serum markers NSE, PS1B rise significantly by the ICD-test as an expression of neuronal 
damage in patients with poor LVEF also significantly more (Prull et al., 2011). In the 
primary prophylaxis ICD indication ICD-test must be therefore a critical indication. 
Additional data from ongoing prospective ICD registries and/or clinical trials are required 
to clarify whether routine DFT testing may be safely abandoned leading to a revision of 
current guidelines. 
3. Lead-related complications 
3.1 Lead Implantation-related complications 
3.1.1 Lead dislocation/malposition 
Device leads are placed routinely with few notable complications. The lead dislocation 
occurs very early postoperative (usually 24–48 hours) but may occur up to 3 months after 
implantation. Adverse changes in sensing and pacing thresholds compared to implant 
values should prompt consideration of this complication and lead repositioning or 
replacement is required. Further management to avoid recurrence of this complication is 
essential and the follow-up of devices early postoperative will help to minimize her 
incidence. 
The lead malposition is diagnosed by unacceptable pacing, sensing, and/or defibrillation 
thresholds. The placement of leads into the left ventricle is a rare complication of 
transvenous device implantation and may be occur by intracardiac abnormality such as a 
ventricular septal defect. This malpositioning places the patients at risk for thromboembolic 
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events, including cerebrovascular insults (37% based on the reported cases of left ventricular 
leads, Van Gelder et al., 2000) and anticoagulation with warfarin is recommended. The 
median sternotomy or thoracotomy are the usual operative technique for the extraction of 
left ventricular lead. It was also reported a successful percutaneous removal of a left 
ventricular lead in patients who had been anticoagulated and had no evidence of thrombus 
on the lead (Trohman et al., 1991) or a minimally invasive technique for left ventricular lead 
extraction (Stouffer et al., 2010).  
Diaphragmatic stimulation is another possible manifestation of lead malposition. It is 
usually due to direct phrenic nerve stimulation from the right or left ventricular lead.  
Location of the left ventricular pacing lead is one of the determinants for success of cardiac 
resynchronization therapy (CRT). The implantation procedure includes several challenging 
technical issues and strongly depends on the highly variable anatomy of the coronary sinus. 
The optimal position of the LV pacing lead is the site of latest activation in the left ventricle, 
which enables effective resynchronization. Furthermore, phrenic nerve stimulation (PNS) 
occurs in 37% of CRT patients at implant or follow-up. To address this common problem, 
the manufacturers of CRT devices offer a range of configurations aimed at preventing PNS. 
A quadripolar LV lead has recently been designed which provides more programming 
configurations and may help to overcome high thresholds and PNS (Forleo GB et al., 2010; 
Shetty AK et al., 2011). There are several publications concerning quadripolar electrode 
implantation which show elimination of PNS, but the optimal LV pacing configuration 
should be determined on the basis of individual patient testing. We report a case in which 
the use of the quadripolar left ventricular lead pacing depended on the highly variable 
anatomy of the coronary sinus and resulted in the occurrence of stable PNS at 3- and 6-
months follow-up. In this case report, even 10/10 configurations could not prevent 
occurrence of PNS (Parahuleva et al., 2011) 
3.1.2 Lead fractures 
Most dislodgements tended to occur in the 3 months following implantation, whereas lead 
fractures continued to occur throughout follow-up. Fractures of ICD leads may occur 5 
years after the implantation and coaxial polyurethane leads have a particularly high 
incidence of failure. However, there are no parameters that can be used to predict lead 
failure during follow-up (Kitamura et al., 2006). Although implantation techniques and 
generator technology continue to evolve, the occurrence of lead fractures and the need for 
premature system revision supports the practice of close routine ICD system surveillance. 
3.1.3 Lead perforation and cardiac tamponade 
The device lead may perforate the atria, ventricle or coronary sinus during the implant 
procedure. Atrial leads perforated more frequently than ventricular leads, and ventricular 
ICD leads perforated more frequently than ventricular pacemaker leads. This 
complication almost always occurs after active fixation of pacing and ICD leads and may 
be associated with delayed right ventricular perforation and bleeding in to the pericardial 
space. Asymptomatic perforation is a common phenomenon with subacute or delayed 
perforation and without clinical signs (inappropriate shock, syncope, abdominal pain, 
mammary hematoma, diaphragm stimulation, and chest pain) of lead perforation at the 
time of the procedure or perforation of the right ventricle diagnosed more then 5 days 
(sometimes more then 6 months) after implantation. However, dyspnea with pericardial 
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effusion may occur requiring emergency pericardial drainage by cardiac tamponade. The 
risk of cardiac tamponade is increased in anticoagulated patients. Subacute ventricular 
perforation is a rare but potentially life threatening complication of lead implantation and 
the diagnosis could be emergency confirmed by chest x-ray, echocardiography, or 
computed tomography. A lead perforation rate is low and there were no statistically 
significant differences in perforation or dislodgement rates between manufacturers or 
lead models (Turakhia et al., 2009). 
3.2 Lead extraction-related complication 
Transvenous lead extraction is an essential component of management of infections and 
other device-related complications (Smith et al., 2008). Despite the development of more 
efficient and safer tools, the procedure continues to be associated with risk of major 
complications such as venous or myocardial damage, tamponade, and even death (Field et 
al. 2007). It has also been recognized that chronic leads (more than 1 year) occasionally break 
during the process of extraction and extraction of a fractured lead from the right ventricle is 
sometimes difficulty.  
Thus, implantation of an additional device lead versus extraction of the defective lead and 
implantation of a new one is one possible therapeutic approach in cases of a defective lead. 
Implantation of an additional or replacement of the lead in case of high-voltage pace/sense 
lead failure is statistically not different concerning mortality and morbidity (Wollmann et 
al., 2007). There are no predictors for further lead defects. Implantation of an additional lead 
should not be recommended in young patients. Predictors for death were an age over 70 
years and renal insufficiency.  
4. Pacing/sensing-related complications 
Pacing/sensing-related and ICD-specific complications (oversensing, undersensing, exit 
block, pacemaker-mediated tachycardia, ineffective and inappropriate therapy) detected 
during routine follow-up visits are relatively rare. Recommended routine follow-up 
intervals for ICD patients are range from 3 to 6 months and 6 month follow-up interval 
appear to be the safest (Senges-Becker et al., 2005). In addition, inappropriate 
pacing/sensing parameters of right ventricular lead implanted at the right ventricular apex 
could occur in the perioperative period. An alternate location for implantation in these 
situations is the right ventricular outflow tract. However, active-fixation of  right ventricular 
leads should be considered to limit the risk of electrode dislodgment (Lubinski et al. 2000). 
5. Complications after ICD replacement and/or upgrade procedures 
Device replacement is generally technically less challenging than a new implant but is 
associated with complications that may place the patient at substantial risk, including 
system infection requiring complete extraction (Gould et al., 2008; Moore et al., 2009). 
Patients who undergo ICD replacement or upgrade procedures often have significant 
cardiac conditions and noncardiac comorbidities and may therefore be at higher risk of 
developing complications from the procedure than has been demonstrated in randomized 
trials (Poole et al., 2010; Santini et al., 2006). The Canadian Heart Rhythm Society has 
previously reported on a retrospective series that involved 533 ICDs that were replaced 
because of an advisory, which demonstrated an overall complication rate of 8.1% (Gould et 
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al., 2006). This unexpectedly high complication rate was associated with major 
complications in 2.0% of patients, including death in 2 patients. A voluntary German ICD 
registry focusing on new implants reported rates of specific complications and found that 
pocket hematoma, chronic pain, and lead and device dislodgments leading to operative 
revisions were the most common events, with reoperation in 3.0% (Gradaus et al., 2003). 
Recently, the REPLACE registry reported a 4.0% complication rate in 1031 patients 
undergoing generator replacement and 15.3% in 713 patients with replacement and a lead 
addition (Poole et al., 2010). This prospective registry reported that ICDs and particularly 
CRT ICDs were associated with a greater risk of complications, consistent with the current 
study that found a higher complication in upgrade and CRT patients. However, identifying 
factors contributing to complications may permit identification of high-risk individuals that 
warrant incremental monitoring and therapy to attenuate risk. Recently, a prospective, 
multicenter, population-based registry of all ICD patients at 18 centers in Ontario, Canada 
showed, that risk factors associated with complications after ICD replacement, include the 
presence of angina, antiarrhythmic therapy, increased number of previous procedures, and 
low implanter volume (Krahn et al., 2011). Generator change is a higher risk procedure than 
new implants. This suggests that clinicians and researchers should consider strategies to 
minimize the need for device replacement, particularly because most devices are implanted 
for primary prevention.  
6. Conclusion 
Cardiovascular implantable cardioverter defibrillator-related complications are rare in 
patients with transvenous device implantation. The cardioverter-defibrillator can be life 
saving, but its potential complications could be significant and enormous. For this reason, 
the recognition of potential cardiovascular implantable cardioverter defibrillator-related 
complications is essential for advances in ICD technology and management strategies to 
avoid their recurrence and will assist and educate clinicians who care for an increasing 
number of patients with cardiovascular devices to minimize the incidence of this 
complication. 
7. Acknowledgment 
Very special thanks to Mr Svetozar Borislavov, for his loving support and understanding 
during my scientific and medical researches in past few years. His encouragement was the 
reason to complete this book chapter and I want to dedicate it to him.  
8. References 
Aggarwal RK, Connelly DT, Ray SG, Ball J, Charles RG. Early complications of permanent 
pacemaker implantation: no difference between dual and single chamber systems. 
Br Heart J, 1995, 73: 571–5. 
Aleksic I, Kottenberg-Assenmacher E, Kienbaum P, Szabo AK, Sommer SP, Wieneke H et al. 
The innominate vein as an alternative venous access for complicated implantable 
cardioverter defibrillator revisions. PACE, 2007, 30:957–60. 
Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in 
orally anticoagulated patients. Pacing Clin Electrophysiol, 2003, 26:511– 4. 
www.intechopen.com
Cardiovascular Implantable Cardioverter Defibrillator-Related  
Complications: From Implant to Removal or Replacement: A Review 
 
111 
Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH. Patient 
and implanting physician factors associated with mortality and complications after 
implantable cardioverter-defibrillator implantation, 2002–2005. Circ Arrhythm 
Electrophysiol, 2008, 1:240–249. 
Allred JD, McElderry HT, Doppalapudi H, Yamada T, Kay GN. Biventricular ICD 
implantation using the iliofemoral approach: providing CRT to patients with 
occluded superior venous access. Pacing Clin Electrophysiol, 2008 Oct;31(10):1351-4. 
Antonelli D, Turgeman Y, Kaveh Z, Artoul S, Rosenfeld T. Short term thrombosis after 
transvenous permanent pacemaker insertion. PACE, 1989, 12:280–2. 
Antonelli D, Freedberg NA, Turgeman Y. Supraclavicular vein approach to overcoming 
ipsilateral chronic subclavian vein obstruction during pacemaker-ICD lead revision 
or upgrading. Europace, 2010 Nov, 12(11):1596-9. 
Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, Cecchin F. 
Age, size, and lead factors alone do not predict venous obstruction in children and 
young adults with transvenous lead systems. J Cardiovasc Electrophysiol. 2006 Jul, 
17(7):754-9. 
Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, 
Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer 
SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder IC, Wilde AA, van 
Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely 
subcutaneous implantable cardioverter-defibrillator. N Engl J Med, 2010 Jul 1, 
363(1):36-44. 
Belott P, Reynolds D. Permanent pacemaker and implantable cardioverterdefibrillator 
implantation. In Ellenboggen K, Kay G, Wilkoff B (Eds): Clinical cardiac pacing and 
defibrillation. WB Saunders, Philadelphia: Saunders; 2000, 573–644. 
Birnie D, Tung S, Simpson C, Crystal E, Exner D, Ayala Paredes FA, et al. Complications 
associated with defibrillation threshold testing: the Canadian experience. Heart 
Rhythm, 2008, 5:387-90. 
Bosa-Ojeda F, Bethencourt-Munoz M, Vergara-Torres M, Lara-Paoron A, Rodriguez-
Gonzales A, Marrero-Rodriguez F. Upgrade of a pacemaker defibrillator to a 
biventricular device: the internal jugular vein approach in a case of bilateral 
subclavian veins occlusion. J Interv Card Electrophysiol, 2007, 19:209–11. 
Brodsky CM, Chang F, Vlay SC. Multicenter evaluation of implantable cardioverter 
defibrillator testing after implant: the Post Implant Testing Study (PITS). Pacing 
Clin Electrophysiol, 1999, 22:1769-76. 
Bulur S, Vural A, Yazıcı M, Ertaş G, Özhan H, Ural D. Incidence and predictors of 
subclavian vein obstruction following biventricular device implantation. J Interv 
Card Electrophysiol, 2010 Dec, 29(3):199-202, Epub 2010 Oct 2. 
Citerne O, Gomes S, Scanu P, Milliez P. Painful Eczema mimicking pocket infection in a 
patient with an ICD: a rare cause of skin allergy to nickel/cobalt alloy. Circulation, 
2011 Mar 22, 123(11):1241-2. 
Curtis JP, Luebbert JJ, Wang Y, Rathore SS, Chen J, Heidenreich PA, Hammill SC, Lampert 
RI, Krumholz HM. Association of physician certification and outcomes among 
patients receiving an implantable cardioverter-defibrillator. JAMA, 2009, 301:1661–
1670 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
112 
Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J; 
American College of Chest Physicians. The perioperative management of 
antithrombotic therapy: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (8th Edition). Chest, 2008 Jun, 133(6 Suppl):299S-339S. 
EN540, European Standard. Clinical Investigation of Medical Devices for Human Subjects, 1993, 
Brussels, Belgium: European Committee for Standardization. 
Field ME, Jones SO, Epstein LM. How to select patients for lead extraction. Heart Rhythm 
2007;4:978-85. 
Forleo GB, Della Rocca DG, Papavasileiou LP, Di Molfetta A, Santini L, Romeo F. Left 
ventricular pacing with a new quadripolar transvenous lead for CRT: early results 
of a prospective comparison with conventional implant outcomes. Heart Rhythm, 
2010, Sep 28. 
Fox DJ, Petkar S, Davidson NC, Fitzpatrick AP. Upgrading patients with chronic 
defibrillator leads to a biventricular system and reducing patient risk: controlateral 
LV lead placement. PACE, 2006, 29:1025–7. 
Gaca JG, Lima B, Milano CA, Lin SS, Davis RD, Lowe JE, Smith PK. Laser-assisted extraction 
of pacemaker and defibrillator leads: the role of the cardiac surgeon. Ann Thorac 
Surg. 2009 May;87(5):1446-50; discussion 1450-1. 
Giudici MC, Barold SS, Paul DL, Bontu P. Pacemaker and implantable cardioverter 
defibrillator implantation without reversal of warfarin therapy. Pacing Clin 
Electrophysiol, 2004, 27:358–60. 
Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral 
cardioverter-defibrillator implantation: comparison of subcutaneous and 
submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol, 1996 
Nov 1, 28(5):1278-82. 
Gondi B, Nanda NC. Real-time, two-dimensional echocardiographic features of pacemaker 
perforation. Circulation, 1981, 64: 97–106. 
Goto, Y., Abe, T., Sekine, S., & Sakurada, T. (1998). Long-term thrombosis after transvenous 
permanent pacemaker implantation. Pacing and Clinical Electrophysiology, 21(6), 
1192–1195. 
Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C, Thibault B, Pinter A, 
Tung S, Sterns L, Birnie D, Exner D, Parkash R, Skanes AC, Yee R, Klein GJ, Krahn 
AD. Outcome of advisory implantable cardioverter-defibrillator replacement: one-
year follow-up. Heart Rhythm, 2008, 5:1675–1681. 
Gould PA, Krahn AD. Complications associated with implantable cardioverter-defibrillator 
replacement in response to device advisories. JAMA, 2006, 295:1907–1911 
Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W, Kranig W, Mletzko 
RU, Schoels W, Seidl K, Senges J, Siebels J, Steinbeck G, Stellbrink C, Andresen D. 
Mortality, morbidity, and complications in 3344 patients with implantable 
cardioverter defibrillators: results from the German ICD Registry EURID. Pacing 
Clin Electrophysiol, 2003, 26:1511–1518. 
Gula LJ, Massel D, Krahn AD, Yee R, Skanes AC, Klein GJ. Is defibrillation testing still 
necessary? A decision analysis and Markov model. J Cardiovasc Electrophysiol, 2008, 
19:400-5. 
Haghjoo, M., Nikoo, M. H., Fazelifar, A. F., Alizadeh, A., Emkanjoo, Z., & Sadr-Ameli, M. A. 
Predictors of venous obstruction following pacemaker or implantable 
www.intechopen.com
Cardiovascular Implantable Cardioverter Defibrillator-Related  
Complications: From Implant to Removal or Replacement: A Review 
 
113 
cardioverterdefibrillator implantation: a contrast venographic study on 100 patients 
admitted for generator change, lead revision, or device upgrade. Europace, (2007), 
9(5), 328–332. 
Healey JS, Birnie DH, Lee DS, Krahn AD, Crystal E, Simpson CS, Dorian P, Chen Z, 
Cameron D, Verma A, Connolly SJ, Gula LJ, Lockwood E, Nair G, Tu JV; Ontario 
ICD Database Investigators. Defibrillation Testing at the Time of ICD Insertion: An 
Analysis From the Ontario ICD Registry. J Cardiovasc Electrophysiol, 2010 Dec, 
21(12):1344-8. 
Hess CN, Ohman EM, Patel MR.Amplatzer vascular plug closure of a subclavian 
arteriovenous fistula associated with implantable cardioverter-defibrillator 
implantation. Catheter Cardiovasc Interv, 2010 Sep 17. 
Hodgson DM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of 
defibrillation thresholds with an active pectoral pulse generator lead system. Pacing 
Clin Electrophysiol, 2002, 25:408-13. 
ISO 14155, International Standard for Clinical Investigation of Medical Devices, Geneva, 
Switzerland: International Organisation for Standardization, 1996. 
Jaroszewski DE, Altemose GT, Scott LR, Srivasthan K, Devaleria PA, Lackey J et al. Non 
traditional surgical approaches for implantation of pacemaker and cardioverter 
defibrillator systems in patients with limited venous access. Ann Thorac Surg, 2009, 
88:112–6. 
Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after 
pacemaker implantation: infection rates and risk factors associated with infection in 
a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011 
Apr;32(8):991-8. Epub 2011 Jan 20. 
Kim JB, Joung B, Lee MH, Kim SS. Use of a tunneling technique to achieve a lower 
defibrillation threshold during implantable cardioverter defibrillator implantation 
via the right subclavian vein. J Korean Med Sci, 2010 Oct, 25(10):1526-8. 
Kitamura S, Satomi K, Kurita T, Shimizu W, Suyama K, Aihara N, Niwaya K, Kobayashi J, 
Kamakura S. Long-term follow-up of transvenous defibrillation leads: high 
incidence of fracture in coaxial polyurethane lead. Circ J, 2006 Mar, 70(3):273-7. 
Korkeila P, Ylitalo A, Koistinen J, Airaksinen KE. Progression of venous pathology after 
pacemaker and cardioverter-defibrillator implantation: A prospective serial 
venographic study. Ann Med, 2009, 41(3):216-23. 
Krahn AD, Lee DS, Birnie D, Healey JS, Crystal E, Dorian P, Simpson CS, Khaykin Y, 
Cameron D, Janmohamed A, Yee R, Austin PC, Chen Z, Hardy J, Tu JV; for the 
Ontario ICD Database Investigators. Predictors of Short-Term Complications After 
Implantable Cardioverter-Defibrillator Replacement: Results From the Ontario ICD 
Database. Arrhythm Electrophysiol, 2011 Apr 1, 4(2):136-142. 
Kron J. Clinical significance of device-related complications in clinical trials and implications 
for future trials: insights from the Antiarrhytmics Versus Implantable Defibrillators 
(AVID) trial. Card Electrophysiol Rev. 2003 Dec;7(4):473-8. 
Laborderie J, Barandon L, Ploux S, Deplagne A, Mokrani B, Reuter S, Le Gal F, Jais P, 
Haissaguerre M, Clementy J, Bordachar P. Management of subacute and delayed 
right ventricular perforation with a pacing or an implantable cardioverter-
defibrillator lead. Am J Cardiol, 2008 Nov 15, 102(10):1352-5. 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
114 
Lickfett L, Bitzen A, Arepally A, Nasir K, Wolpert C, Jeong KM et al. Incidence of venous 
obstruction following insertion of an implantable cardioverter defibrillator. A study 
of systematic contrast venography on patients presenting for their first elective ICD 
generator replacement. Europace, 2004, 6:25–31. 
Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. Device 
complications and inappropriate implantable cardioverter defibrillator shocks in 
patients with hypertrophic cardiomyopathy. Heart, 2009 May, 95(9):709-14. 
Lubinski A, Lewicka-Nowak E, Królak T, Kempa M, Bielawska B, Wilczek R, Swiatecka G. 
Implantation and follow-up of ICD leads implanted in the right ventricular outflow 
tract. Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1996-8. 
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of 
surgical site infection, 1999. Hospital Infection Control Practices Advisory 
Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78. 
Margey R, McCann H, Blake G, Keelan E, Galvin J, Lynch M, Mahon N, Sugrue D, O'Neill J. 
Contemporary management of and outcomes from cardiac device related 
infections. Europace. 2010 Jan;12(1):64-70. 
Mela T, McGovern BA, Garan H, Vlahakes GJ, Torchiana DF, Ruskin J, Galvin JM. Long-
term infection rates associated with the pectoral versus abdominal approach to 
cardioverter- defibrillator implants. Am J Cardiol. 2001 Oct 1;88(7):750-3. 
Merla R, Reddy NK, Kunapuli S, Schwarz E, Vitarelli A, Rosanio S. Late right ventricular 
perforation and hemothorax after transvenous defibrillator lead implantation. Am J 
Med Sci, 2007 Sep, 334(3):209-11. 
Moore JW III., Barrington W, Bazaz R, Jain S, Nemec J, Ngwu O, Schwartzman D, Shalaby 
A, Saba S. Complications of replacing implantable devices in response to 
advisories: a single center experience. Int J Cardiol, 2009, 134:42–46. 
Parahuleva M, Chasan R, Soydan N, Abdallah Y, Neuhof Ch, Tillmanns H, Erdogan A. 
Quadripolar left ventricular lead in a patient with CRT-D does not overcome 
phrenic nerve stimulation. Clin Med Insights Cardiology, 2011:5 45–47. 
Parahuleva M, Schifferings P, Neuhof Ch, Tillmanns H, Erdogan A. Pneumopericardium 
and Pneumomediastinum as a Late Complication of Defibrillator Implantation after 
Coronary Artery Bypass Graft Surgery. Thorac Cardiov Surg, 2009, 57:489–495. 
Pavia S, Wilkoff B. The management of surgical complications of pacemaker and 
implantable cardioverter-defibrillators. Curr Opin Cardiol, 2001 Jan, 16(1):66-71. 
Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, Shinn T, Dan D, 
Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell K, Holcomb 
R. Complication rates associated with pacemaker or implantable cardioverter-
defibrillator generator replacements and upgrade procedures: results from the 
REPLACE registry. Circulation, 2010, 122:1553–1561. 
Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, Simon AW. The 
frequency and incremental cost of major complications among medicare 
beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol, 
2006 Jun 20, 47(12):2493-7. 
Prull M. W, Unverricht S, Bittlinsky A, Sasko B, Wirdemann H, Gkiouras G, Butz T, Trappe 
H.-J. Der ICD-Test führt zu einem zerebralen Schaden und verschlechtert die 
kognitive Funktion. Clin Res Cardiol, 100, Suppl 1, April 2011 
www.intechopen.com
Cardiovascular Implantable Cardioverter Defibrillator-Related  
Complications: From Implant to Removal or Replacement: A Review 
 
115 
Rosman J, Shapiro MD, Hanon S. Pneumomediastinum and right sided pneumothorax 
following dual chamber-ICD implantation. J Interv Card Electrophysiol, 2006 Nov, 
17(2):157-8. 
Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, et al. Defibrillation 
threshold testing: is it really necessary at the time of implantable cardioverter-
defibrillator insertion? Heart Rhythm, 2005, 2:456-61. 
Santini M, Brachmann J, Cappato R, Davies W, Farre J, Levy S, Quesada A, Ricci RP, 
Rowland E, Sulke N. Recommendations of the European Cardiac Arrhythmia 
Society Committee on device failures and complications. Pacing Clin Electrophysiol, 
2006, 29:653–669. 
Senges-Becker JC, Klostermann M, Becker R, Bauer A, Siegler KE, Katus HA, Schoels W. 
What is the "optimal" follow-up schedule for ICD patients? Europace. 2005 
Jul;7(4):319-26. 
Shetty AK, Duckett SG, Bostock J, Roy D, Ginks M, Hamid S, Rosenthal E, Razavi R, Rinaldi 
CA. Initial Single-Center Experience of a Quadripolar Pacing Lead for Cardiac 
Resynchronization Therapy. Pacing Clin Electrophysiol, 2011 Jan 5. 
Smith MC, Love CJ. Extraction of transvenous pacing and ICD leads. Pacing Clin 
Electrophysiol 2008;31:736-52. 
Spencker S, Coban N, Koch L, Schirdewan A, Mueller D. Comparison of skin adhesive and 
absorbable intracutaneous suture for the implantation of cardiac rhythm devices. 
Europace, 2011 Mar, 13(3):416-20, Epub 2010 Nov 11. 
Stark, J.N. (2011). A New Standard for Medical Device Investigations. Journal of 
ClinicalResearch Best Practices, Vol. 7, No. 2, (February 2011) 
Stouffer CW, Shillingford MS, Miles WM, Conti JB, Beaver TM. Lead astray: minimally 
invasive removal of a pacing lead in the left ventricle. Clin Cardiol, 2010 Jun, 
33(6):E109-10. 
Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? J 
Am Coll Cardiol, 2004, 44:88-91. 
Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, 
Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA. Dual 
antiplatelet therapy and heparin "bridging" significantly increase the risk of 
bleeding complications after pacemaker or implantable cardioverter-defibrillator 
device implantation. J Am Coll Cardiol, 2010 May 25, 55(21):2376-82. 
Trohman RG, Wilkoff BL, Byrne T, et al. Successful percutaneous extraction of a chronic left 
ventricular pacing lead. Pacing Clin Electrophysiol, 1991, 14:1448–1451. 
Turakhia M, Prasad M, Olgin J, Badhwar N, Tseng ZH, Lee R, Marcus GM, Lee BK. Rates 
and severity of perforation from implantable cardioverter-defibrillator leads: a 4-
year study. J Interv Card Electrophysiol. 2009 Jan;24(1):47-52. 
Van Gelder BM, Bracke FA, Oto A, et al. Diagnosis and management of inadvertently placed 
pacing and ICD leads in the left ventricle: a multicenter experience and review of 
the literature. Pacing Clin Electrophysiol, 2000, 23:877–883. 
Van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman MV. 
Incidence and risk factors of early venous thrombosis associated with permanent 
pacemaker leads. J Cardiovasc Electrophysiol, 2004 Nov, 15(11):1258-62. 
Veltri EP, Mower MM, Reid PR. Twiddler's syndrome: a new twist. PACE, 1984, 7:1004-09 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
116 
Wilkoff BL. Lead-induced venous thrombosis:consequences? J Cardiovasc Electrophysiol, 2004 
Nov, 15(11):1263-4. 
Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, 
Howlett JG, Kautzner J, Love CJ, Morgan JM, Priori SG, Reynolds DW, Schoenfeld 
MH, Vardas PE; (HRS; EHRA; ACC; AHA); European Society of Cardiology (ESC); 
Heart Failure Association of ESC (HFA); Heart Failure Society of America (HFSA). 
HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable 
Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, 
Frequency and Ethical Considerations. Europace, 2008 Jun, 10(6):707-25. 
Wollmann CG, Böcker D, Löher A, Paul M, Scheld HH, Breithardt G, Gradaus R.Two 
different therapeutic strategies in ICD lead defects: additional combined lead 
versus replacement of the lead. J Cardiovasc Electrophysiol, 2007 Nov, 18(11):1172-7. 
Worley SJ, Ghon DC, Pulliam RW. Opening an occluded subclavian vein with a screw-like 
flexible hollow guide-wire and venoplasty. PACE, 2007, 30:1290–3. 
www.intechopen.com
Cardiac Defibrillation - Mechanisms, Challenges and Implications
Edited by Prof. Natalia Trayanova
ISBN 978-953-307-666-9
Hard cover, 248 pages
Publisher InTech
Published online 26, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The only known effective therapy for lethal disturbances in cardiac rhythm is deï¬​brillation, the delivery of a
strong electric shock to the heart. This technique constitutes the most important means for prevention of
sudden cardiac death. The efficacy of defibrillation has led to an exponential growth in the number of patients
receiving implantable devices. The objective of this book is to present contemporary views on the basic
mechanisms by which the heart responds to an electric shock, as well as on the challenges and implications of
clinical defibrillation. Basic science chapters elucidate questions such as lead configurations and the reasons
by which a defibrillation shock fails. Chapters devoted to the challenges in the clinical procedure of defibrillation
address issues related to inappropriate and unnecessary shocks, complications associated with the
implantation of cardioverter/defibrillator devices, and the application of the therapy in pediatric patients and
young adults. The book also examines the implications of defibrillation therapy, such as patient risk
stratification, cardiac rehabilitation, and remote monitoring of patient with implantable devices.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mariana Parahuleva (2011). Cardiovascular Implantable Cardioverter Defibrillator-Related Complications:
From Implant to Removal or Replacement: A Review, Cardiac Defibrillation - Mechanisms, Challenges and




© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
